856
S. SEN ET AL.
REFERENCES
1. Chorghade, M. S. In Drug Discovery and Development; John Wiley & Sons: Hoboken, NJ,
2007, Vol. 2.
2. Lednicer, D.; Mitscher, L. A. In The Organic Chemistry of Drug Synthesis; John Wiley &
Sons: New York, 1977; Vol. 1.
3. Singh, S.; Yadav, A.; Meena, A. K. Pharmacological action and SAR of phthalazine deri-
vatives: A review. Internat. J. Chem. Anal. Sci. 2010, 1, 79–87.
4. Grasso, S.; Desarro, G.; Micale, N.; Zappala, M.; Puia, G.; Baraldi, M.; Demicheli, C. Syn-
thesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2-
H)-ones. J. Med. Chem. 2000, 43, 2851–2859.
5. Ryu, C.-K.; Park, R.-E.; Ma, M.-Y.; Nho, J.-H. Synthesis and antifungal activity of
6-arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones. Bioorg.
Med. Chem. Lett. 2007, 17, 2577–2580.
6. Kim, J. S.; Rhee, H. K.; Park, H. J.; Lee, S. K.; Lee, C. O.; Park, C. H. Y. Synthesis of 1-=
2-substituted-[1,2,3]triazolo[4,5-g]phthalazine-4,9-diones and evaluation of their cytotoxi-
city and topoisomerase II inhibition. Bioorg. Med. Chem. 2008, 16, 4545–4550.
7. Cockcroft, X.; Dillon, K. J.; Dixon, L.; Drzewiecki, J.; Eversley, P.; Gomes, S.; Hoare, J.;
Kirrigan, F.; Natthews, I.; Menear, K. A.; Martin, N. M. B.; Newton, R.; Paul, J.; Smith,
G. C. M.; Vile, J.; Whittlr, A. Phthalazinones 2: Optimisation and synthesis of novel
potent inhibitors of poly(ADP-ribose)polymerase. J. Bioorg. Med. Chem. Lett. 2006, 16,
1040–1044.
8. Cockcroft, X.; Dillon, K. J.; Dixon, L.; Drzewiecki, J.; Kirrigan, F.; Loh, V. M.; Martin,
N. M. B.; Menear, K. A.; Smith, G. C. M. Phthalazinones, part 1: The design and syn-
thesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg.
Med. Chem. Lett. 2005, 15, 2235–2238.
9. Kim, J. S.; Lee, H.; Suh, M.; Choo, H. P.; Lee, S. K.; Park, H. J.; Kim, C.; Park, S. W.;
Lee, C. Synthesis and cytotoxicity of 1-substituted 2-methyl-1H-imidazo[4,5-
g]phthalazine-4,9-dione derivatives. Bioorg. Med. Chem. 2004, 12, 3683–3686.
10. Haikal, A.; El-Ashery, E.; Banoub, J. Synthesis and structural characterization of
1-(D-glycosyloxy)phthalazines. Carbohydr. Res. 2003, 338, 2291–2299.
11. Demirayak, S.; Karaburun, A.; Beis, R. Some pyrrole substituted aryl pyridazinone and
phthalazinone derivatives and their antihypertensive activities. Eur. J. Med. Chem. 2004,
39, 1089–1095.
12. Watanabe, N.; Kabasawa, Y.; Takase, Y.; Matsukura, M.; Miyazaki, K.; Ishihara, H.;
Kodama, K.; Adashi, H. 4-Benzylamino-1-chloro-6-substituted phthalazines: Synthesis
and inhibitory activity toward phosphodiesterase 5. J. Med. Chem. 1998, 41, 3367–3372.
13. Madhavan, G. R.; Chakrabarti, R.; Kumar, S. K.; Misra, P.; Mamidi, R. N.; Balraju, V.;
Ksiram, K.; Babu, R. K.; Suresh, J.; Lohray, B. B.; Lohray, V. B.; Iqbal, J.; Rajagopalan,
R. Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic
and hypolipidemic agents. Eur. J. Med. Chem. 2001, 36, 627–637.
14. Lenz, E. M.; Wilson, I. D.; Wright, B.; Partidge, E. A.; Roddgers, C. T.; Haycock, P. R.;
Lindon, J. C.; Nicholson, J. K. A comparison of quantitative NMR and radiolabelling
studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-
3H-phthalazin-1-ylacetic acid) in the rat. J. Pharm. Biomed. Anal. 2002, 28, 31–43.
15. Carling, R. W.; Moore, K. W.; Street, L. J.; Wild, D.; Isted, C.; Leeson, P. D.; Thomas, S.;
O’Connor, D.; McKernan, R. M.; Quirk, K.; Cook, S. M.; Atack, J. R.; Wafford, K. A.;
Thompson, S. A.; Dawson, G. R.; Ferris, P.; Castro, J. L. 3-Phenyl-6-
(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and Analogues: High-affinity c-
aminobutyric acid-A benzodiazepine receptor ligands with a2-, a3-, and a5-subtype
binding selectivity over a1. J. Med. Chem. 2004, 47, 1807.